Company / Operating Income
Fulcrum Therapeutics, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$84.8M
FY2025
5-year range
-$112.6M / -$21.9M
FY2021-FY2025
Trend
-287.1%
vs FY2024
Sector context
#85 of 204
Health Care
What the data says
Operating Income changed -287% YoY in FY2025, a notable deviation from the 7-year average annual change of -56%.
Based on SEC 10-K filings.
-$85M in FY2025.
Improved from -$111M to -$85M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#85 of 204 in Health CareTop 42% of 204This company -$84.8M Sector average $107.7M
▼
-178.7% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 287.1% year-over-year.
- Ranks #85 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2024.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$84.8M | -287.1% |
| FY2024 | -$21.9M | +80.2% |
| FY2023 | -$110.7M | +1.7% |
| FY2022 | -$112.6M | -38.9% |
| FY2021 | -$81.1M | -13.2% |
| FY2020 | -$71.6M | +15.0% |
| FY2019 | -$84.2M | -151.4% |
| FY2018 | -$33.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026